Citizens JMP lowered the firm’s price target on Quince Therapeutics (QNCX) to $8 from $9 and keeps an Outperform rating on the shares. The firm is impressed with management’s execution in completing enrollment for the pivotal NEAT trial, which is set up for success, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNCX:
- Quince Therapeutics Reports Q2 2025 Financial Results
- Quince Therapeutics reports Q2 EPS (34c), consensus (23c)
- QNCX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Quince Therapeutics initiated with an Outperform at Citizens JMP
- Quince Therapeutics files to sell 6.67M shares of common stock for holders